Abbasian Sadegh, Razmi Mahya, Bahramian Hadiseh, Shanbehzadeh Mostafa, Kazemi-Arpanahi Hadi
Department of Laboratory Science, School of Paramedical Sciences, Ilam University of Medical Sciences, Ilam, Iran.
Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
Adv Biomed Res. 2023 Jun 28;12:147. doi: 10.4103/abr.abr_403_21. eCollection 2023.
The new coronavirus is an agent of respiratory infections associated with thrombosis in vital organs. This study aimed to propose a better diagnosis and treatment of coagulation disorders caused by the new coronavirus (Covid-19).
Search in Cochrane central, Web of Science, PubMed, Scopus, and Ovid will be done. Also, according to the inclusion criteria, cross-sectional studies, cohort, clinical trial, and case-control will be included without gender and language restriction. Participants will also be Covid-19 patients with coagulation disorders. Any disagreement in the stages of screening, selection, and extraction of data between the two reviewers will be resolved by discussion, then if not resolved, the opinion of expert reviewers will be used. The risk of bias will be assessed using the NOS (Newcastle-Ottawa scale) tool for cross-sectional study, cohort and case-control, and the Cochrane checklist for clinical trials study. Metaanalysis of included studies that are similar based on the methodology will be done. Also, a fixed or random-effect model will be used for this it. Heterogeneity indices (I2), odds ratio (OR), risk ratio (RR), mean difference, and %95 confidence interval will also be calculated by Stata V.13.0 (Corporation, College Station TX).
Treatment with anticoagulants will reduce the severity of thrombosis and lung disease in patients. D-dimer measurement will also be a diagnosis indicator of thrombosis.
Simultaneous study of coagulation disorders and thrombosis in patients and development of a Godliness based on it will play a treatment role in the follow-up of the coronavirus disease.
新型冠状病毒是一种与重要器官血栓形成相关的呼吸道感染病原体。本研究旨在提出对新型冠状病毒（新冠病毒-19）所致凝血障碍的更好诊断和治疗方法。
将检索考克兰中心、科学网、PubMed、Scopus和Ovid。此外，根据纳入标准，将纳入横断面研究、队列研究、临床试验和病例对照研究，无性别和语言限制。参与者还将是患有凝血障碍的新冠病毒-19患者。两位评审员在筛选、选择和数据提取阶段的任何分歧将通过讨论解决，若未解决，则采用专家评审员的意见。将使用NOS（纽卡斯尔-渥太华量表）工具评估横断面研究、队列研究和病例对照研究的偏倚风险，以及临床试验研究的考克兰清单。将对基于方法学相似的纳入研究进行荟萃分析。此外，将为此使用固定或随机效应模型。异质性指数（I2）、比值比（OR）、风险比（RR）、平均差和95%置信区间也将通过Stata V.13.0（德克萨斯州大学站公司）计算。
抗凝治疗将降低患者血栓形成和肺部疾病的严重程度。D-二聚体检测也将是血栓形成的诊断指标。
对患者凝血障碍和血栓形成进行同步研究并据此制定诊疗方案，将在冠状病毒病的后续治疗中发挥作用。
